Aaron T. Gerds

6.7k total citations
260 papers, 2.4k citations indexed

About

Aaron T. Gerds is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Aaron T. Gerds has authored 260 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 185 papers in Hematology, 175 papers in Genetics and 47 papers in Molecular Biology. Recurrent topics in Aaron T. Gerds's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (160 papers), Acute Myeloid Leukemia Research (100 papers) and Chronic Myeloid Leukemia Treatments (83 papers). Aaron T. Gerds is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (160 papers), Acute Myeloid Leukemia Research (100 papers) and Chronic Myeloid Leukemia Treatments (83 papers). Aaron T. Gerds collaborates with scholars based in United States, United Kingdom and Italy. Aaron T. Gerds's co-authors include Srđan Verstovšek, Mikkael A. Sekeres, Ruben A. Mesa, Bart L. Scott, Vikas Gupta, John Mascarenhas, Claire Harrison, Aziz Nazha, Anjali S. Advani and Sudipto Mukherjee and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Aaron T. Gerds

246 papers receiving 2.4k citations

Peers

Aaron T. Gerds

HEMAT

GENET

ONCOL

RHEUM

Åsa Rangert Derolf Sweden

Alessandra Iurlo Italy

Bart L. Scott United States

Vamsi Kota United States

Jorge Vela‐Ojeda Mexico

Juan Luis Steegmann Spain

Alessandro Corso Italy

William J. Edenfield United States

Marinus van Marwijk Kooy Netherlands

Olivier Decaux France

Åsa Rangert Derolf Sweden

Aaron T. Gerds

2.2k ×1.3

HEMAT

1.2k ×0.9

GENET

1.2k ×1.3

525 ×1.4

ONCOL

393 ×1.1

RHEUM

Citations per year, relative to Aaron T. Gerds Aaron T. Gerds (= 1×) peers Åsa Rangert Derolf

Countries citing papers authored by Aaron T. Gerds

Since Specialization

Citations

This map shows the geographic impact of Aaron T. Gerds's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron T. Gerds with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron T. Gerds more than expected).

Fields of papers citing papers by Aaron T. Gerds

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aaron T. Gerds. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron T. Gerds. The network helps show where Aaron T. Gerds may publish in the future.

Co-authorship network of co-authors of Aaron T. Gerds

This figure shows the co-authorship network connecting the top 25 collaborators of Aaron T. Gerds. A scholar is included among the top collaborators of Aaron T. Gerds based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aaron T. Gerds. Aaron T. Gerds is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wei, Wei, Meriel P Burns, Deepa Jagadeesh, et al.. (2025). Assessment of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplant When Comparing Treatment with and without Post-Transplant Cyclophosphamide. Transplantation and Cellular Therapy. 31(2). S372–S372. 1 indexed citations

Mascarenhas, John, et al.. (2024). The Use of Fedratinib (FEDR) for Myelofibrosis (MF) As a Potential Bridge to Hematopoietic Stem Cell Transplantation (HSCT) after Ruxolitinib (RUX) Failure: Real-World Assessment of Treatment Characteristics and Spleen, Symptoms, and Hematologic Response. Transplantation and Cellular Therapy. 30(2). S372–S372. 1 indexed citations

Bewersdorf, Jan Philipp, Claire Harrison, Francesca Palandri, et al.. (2024). Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST‐2 Landmark Analysis of Survival. European Journal Of Haematology. 114(2). 238–247. 3 indexed citations

Harrison, Claire, Alessandro M. Vannucchi, Christian Récher, et al.. (2024). Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2. Advances in Therapy. 41(9). 3722–3735. 7 indexed citations

Oh, Stephen T., Ruben A. Mesa, Claire Harrison, et al.. (2023). Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Advances. 7(19). 5835–5842. 39 indexed citations

Scandura, Joseph M., et al.. (2023). A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Patients with JAK Inhibitor-Naïve Myelofibrosis and Moderate Thrombocytopenia (XPORT-MF-044). Blood. 142(Supplement 1). 3211–3211. 1 indexed citations

Hamilton, Betty K., Lisa Rybicki, Hong Li, et al.. (2023). Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention. Blood Advances. 7(16). 4505–4513. 4 indexed citations

Kiladjian, Jean‐Jacques, Alessandro M. Vannucchi, Aaron T. Gerds, et al.. (2023). Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials. HemaSphere. 7(11). e963–e963. 10 indexed citations

Mesa, Ruben A., Claire Harrison, Stephen T. Oh, et al.. (2022). Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia. 36(9). 2261–2268. 40 indexed citations

10.

Urban, Theresa, Faiz Anwer, Robert M. Dean, et al.. (2022). Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoring. Journal of Oncology Pharmacy Practice. 32(2). 184–188. 1 indexed citations

11.

Advani, Anjali S., Anna Moseley, Kristen M. O’Dwyer, et al.. (2021). A Phase 2 Study of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive or Ph-like Acute Lymphoblastic Leukemia (ALL) (with Dasatinib Sensitive Fusions/ Mutations). Blood. 138(Supplement 1). 3397–3397. 9 indexed citations

12.

Mascarenhas, John, Francesco Passamonti, Kate Burbury, et al.. (2021). The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. Blood Advances. 6(4). 1162–1174. 16 indexed citations

13.

Kunte, Siddharth, Lisa Rybicki, Auro Viswabandya, et al.. (2021). Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. Leukemia. 36(3). 856–864. 20 indexed citations

14.

Mian, Agrima, Wei Wei, Allison Winter, et al.. (2019). Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis. Blood. 134(Supplement_1). 4452–4452. 5 indexed citations

15.

Mukherjee, Sudipto, Hong Li, Brian P. Hobbs, et al.. (2019). A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy. Blood. 134(Supplement_1). 2595–2595. 1 indexed citations

16.

Hamilton, Betty K., Lisa Rybicki, David Grove, et al.. (2019). Breath analysis in gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Blood Advances. 3(18). 2732–2737. 7 indexed citations

17.

Urban, Theresa, Robert M. Dean, Aaron T. Gerds, et al.. (2019). Evaluation of Corticosteroids for Engraftment Syndrome (ES) Prophylaxis in Patients Undergoing Autologous Hematopoietic Cell Transplantation (AHCT) with High-Dose Melphalan (MEL). Biology of Blood and Marrow Transplantation. 25(3). S281–S281. 1 indexed citations

18.

Gerds, Aaron T., Bart L. Scott, Peter L. Greenberg, et al.. (2018). PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis. Blood. 132(Supplement 1). 466–466. 24 indexed citations

19.

Madanat, Yazan F., Mikkael A. Sekeres, Sudipto Mukherjee, et al.. (2018). Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes. Blood. 132(Supplement 1). 1797–1797. 6 indexed citations

20.

Sekeres, Mikkael A., Babal K. Jha, Bartlomiej Przychodzen, et al.. (2016). TP53 Mutations and Outcome in Patients with Myelodysplastic Syndromes (MDS). Blood. 128(22). 4336–4336. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact